INVESTABOT
Equity Research
XNYS · SERVICES-MEDICAL LABORATORIES · SERVICES-MEDICAL LABORATORIES
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Quest Diagnostics (DGX) had 1 Form 144 pre-sale notice filed on 2026-07-28. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one fi…
Quest Diagnostics (DGX) had 1 Form 144 pre-sale notice filed on 2026-06-04. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one fi…
Quest Diagnostics (DGX) had 1 Form 144 pre-sale notice filed on 2026-06-01. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one fi…
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 7/28/2026 | DELANEY MARK E | SVP & Chief Commercial Officer | SELL | -1,600 | $235 | $376,288 |
| 7/22/2026 | DELANEY MARK E | SVP & Chief Commercial Officer | OTHER | 34 | $207 | $7,031 |
| 7/22/2026 | Lassiter Wright III | — | OTHER | 6 | $207 | $1,241 |
| 7/22/2026 | SAMAD SAM | Executive Vice President & CFO | GRANT | 102 | $207 | $21,094 |
| 7/22/2026 | MAIN TIMOTHY L | — | OTHER | 21 | $207 | $4,343 |
| 7/22/2026 | Plewman Patrick | SVP for Diagnostic Services | OTHER | 46 | $207 | $9,513 |
| 7/22/2026 | Gregg Vicky B | — | GRANT | 72 | $207 | $14,890 |
| 7/22/2026 | CARTER ROBERT B | — | OTHER | 11 | $207 | $2,275 |
| 7/22/2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | OTHER | 37 | $207 | $7,652 |
| 7/1/2026 | WENTWORTH TIMOTHY C | — | GRANT | 144 | — | — |
| 6/4/2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | OPTION_EXERCISE | 3,320 | $128 | $424,047 |
| 6/4/2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | OPTION_EXERCISE | 4,827 | $122 | $587,953 |
| 6/4/2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | SELL | -8,147 | $200 | $1,629,400 |
| 6/4/2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | OPTION_EXERCISE | -3,320 | $128 | $424,047 |
| 6/4/2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | OPTION_EXERCISE | -4,827 | $122 | $587,953 |
| 6/1/2026 | Davis J. E. | CEO and President | SELL | -10,000 | $194 | $1,941,400 |
| 5/20/2026 | PFEIFFER GARY M | — | GRANT | 1,142 | — | — |
| 5/20/2026 | CARTER ROBERT B | — | GRANT | 1,142 | — | — |
| 5/20/2026 | Gregg Vicky B | — | GRANT | 1,142 | — | — |
| 5/20/2026 | Diaz Luis | — | GRANT | 1,142 | — | — |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| Vanguard Group | 14,392,082 | $2,497,458,052 | — | 1/29/2026 |
| BlackRock | 9,275,411 | $1,965,923,399 | 1.1% | 8/7/2026 |
| BlackRock | 9,172,292 | $1,797,585,732 | -3.0% | 5/13/2026 |
| BlackRock | 9,459,218 | $1,641,458,028 | — | 2/12/2026 |
| BlackRock | 10,059,403 | $1,376,931,063 | — | 8/13/2024 |
| State Street | 5,516,643 | $1,169,252,484 | 2.5% | 8/7/2026 |
| State Street | 5,380,821 | $1,054,533,300 | -0.0% | 5/15/2026 |
| State Street | 5,382,547 | $934,033,381 | — | 2/13/2026 |
| JP Morgan Chase | 3,846,456 | $758,367,688 | -7.2% | 5/13/2026 |
| JP Morgan Chase | 3,520,438 | $748,586,197 | -8.5% | 8/12/2026 |
| JP Morgan Chase | 4,145,896 | $719,437,502 | — | 2/11/2026 |
| Morgan Stanley | 2,460,497 | $521,503,271 | -0.8% | 8/13/2026 |
| Morgan Stanley | 2,479,720 | $485,976,070 | -7.9% | 5/15/2026 |
| Morgan Stanley | 2,693,568 | $467,415,402 | — | 5/27/2026 |
| Goldman Sachs | 1,762,925 | $305,920,455 | — | 3/25/2026 |
| Fidelity (FMR) | 1,398,735 | $296,462,102 | 48.5% | 8/13/2026 |
| Goldman Sachs | 1,348,694 | $264,317,118 | -23.5% | 5/15/2026 |
| Fidelity (FMR) | 1,202,254 | $208,627,187 | — | 2/17/2026 |
| Goldman Sachs | 982,694 | $208,282,052 | -27.1% | 8/14/2026 |
| Fidelity (FMR) | 942,218 | $184,655,952 | -21.6% | 5/15/2026 |